Format
Sort by
Items per page

Send to

Choose Destination

Best matches for HYDROXYPROGESTERONE/TU:

Search results

Items: 1 to 20 of 5231

1.
2.

Oral and intrauterine progestogens for atypical endometrial hyperplasia.

Luo L, Luo B, Zheng Y, Zhang H, Li J, Sidell N.

Cochrane Database Syst Rev. 2018 Dec 4;12:CD009458. doi: 10.1002/14651858.CD009458.pub3.

PMID:
30521671
3.
4.

The role of hormonal therapy in patients with uterine carcinoma.

Vinklerová P, Minář L, Felsinger M, Anton M, Ventruba P, Bednaříková M, Hausnerová J, Jandáková E, Číhalová M, Weinberger V.

Ceska Gynekol. Fall 2018;83(4):263-270.

PMID:
30441956
5.

Ugandan providers' views on the acceptability of contraceptive self-injection for adolescents: a qualitative study.

Cover J, Namagembe A, Tumusiime J, Lim J, Cox CM.

Reprod Health. 2018 Oct 3;15(1):165. doi: 10.1186/s12978-018-0611-7.

6.

Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo.

Kagan R, Abreu P, Andrews E.

Postgrad Med. 2018 Nov;130(8):687-693. doi: 10.1080/00325481.2018.1520046. Epub 2018 Oct 3.

PMID:
30280946
7.

Efficacy of progesterone for prevention of preterm birth.

Sykes L, Bennett PR.

Best Pract Res Clin Obstet Gynaecol. 2018 Oct;52:126-136. doi: 10.1016/j.bpobgyn.2018.08.006. Epub 2018 Sep 8. Review.

PMID:
30266582
8.

Changes to the World Health Organization guideline on hormonal contraceptive eligibility for women at high risk of HIV: South African perspective and response.

Nene Z, Hofmeyr GJ, Patel M, Panday M, Rees H, Makua M, Pillay Y.

S Afr Med J. 2018 Jul 25;108(8):629-631. doi: 10.7196/SAMJ.2018.v108i8.13160.

10.

Differential expressions of estrogen and progesterone receptors in endometria and cyst walls of ovarian endometrioma from women with endometriosis and their responses to depo-medroxyprogesterone acetate treatment.

Sroyraya M, Songkoomkrong S, Changklungmoa N, Poljaroen J, Weerakiet S, Sophonsritsuk A, Wongkularb A, Lertvikool S, Tingthanatikul Y, Sobhon P.

Mol Cell Probes. 2018 Aug;40:27-36. doi: 10.1016/j.mcp.2018.07.001. Epub 2018 Jul 3.

PMID:
30078406
11.

Inequality and Innovation: Barriers and Facilitators to 17P Administration to Prevent Preterm Birth among Medicaid Participants.

Cross-Barnet C, Courtot B, Benatar S, Hill I, Johnston E, Cheeks M.

Matern Child Health J. 2018 Nov;22(11):1607-1616. doi: 10.1007/s10995-018-2556-4. Erratum in: Matern Child Health J. 2018 Nov 30;:.

PMID:
29956128
12.

Acceptability of Contraceptive Self-Injection with DMPA-SC Among Adolescents in Gulu District, Uganda.

Cover J, Lim J, Namagembe A, Tumusiime J, Drake JK, Cox CM.

Int Perspect Sex Reprod Health. 2017 Dec 1;43(4):153-162. doi: 10.1363/43e5117.

PMID:
29771679
13.

Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls.

Zeng Z, Jiang X, Li X, Wells A, Luo Y, Neapolitan R.

PLoS One. 2018 May 16;13(5):e0197064. doi: 10.1371/journal.pone.0197064. eCollection 2018.

14.

Rationale for current and future progestin-based therapies to prevent preterm birth.

Weatherborn M, Mesiano S.

Best Pract Res Clin Obstet Gynaecol. 2018 Oct;52:114-125. doi: 10.1016/j.bpobgyn.2018.03.008. Epub 2018 Apr 11. Review.

PMID:
29724668
15.

Dietary intake and eating behavior in depot medroxyprogesterone acetate users: a systematic review.

Silva P, Qadir S, Fernandes A, Bahamondes L, Peipert JF.

Braz J Med Biol Res. 2018;51(6):e7575. doi: 10.1590/1414-431x20187575. Epub 2018 Apr 23. Review.

16.

Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis.

Barra F, Scala C, Ferrero S.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):399-415. doi: 10.1080/17425255.2018.1461840. Epub 2018 Apr 10. Review.

PMID:
29617576
17.

Designing a global monitoring system for pilot introduction of a new contraceptive technology, subcutaneous DMPA (DMPA-SC).

Stout A, Wood S, Namagembe A, Kaboré A, Siddo D, Ndione I.

Eval Program Plann. 2018 Jun;68:185-193. doi: 10.1016/j.evalprogplan.2018.03.004. Epub 2018 Mar 5.

18.

Expanding Access to Injectable Contraception: Results From Pilot Introduction of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in 4 African Countries.

Stout A, Wood S, Barigye G, Kaboré A, Siddo D, Ndione I.

Glob Health Sci Pract. 2018 Mar 30;6(1):55-72. doi: 10.9745/GHSP-D-17-00250. Print 2018 Mar 21.

19.

A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.

Shambhavi S, Bagga R, Bansal P, Kalra J, Kumar P.

J Obstet Gynaecol. 2018 Aug;38(6):800-806. doi: 10.1080/01443615.2018.1425380. Epub 2018 Mar 20.

PMID:
29557230
20.

Effect of self-administration versus provider-administered injection of subcutaneous depot medroxyprogesterone acetate on continuation rates in Malawi: a randomised controlled trial.

Burke HM, Chen M, Buluzi M, Fuchs R, Wevill S, Venkatasubramanian L, Dal Santo L, Ngwira B.

Lancet Glob Health. 2018 May;6(5):e568-e578. doi: 10.1016/S2214-109X(18)30061-5. Epub 2018 Mar 8.

Supplemental Content

Loading ...
Support Center